Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
Holding BSX?
Track your performance easily
BSX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.75 - $91.93
Previous Close$91.07
Volume1.88M
Average Volume (3M)5.84M
Market Cap
$134.22B
Enterprise Value$142.85B
Total Cash (Recent Filing)$2.50B
Total Debt (Recent Filing)$10.88B
Price to Earnings (P/E)75.3
Beta0.76
Next Earnings
Jan 29, 2025EPS Estimate
$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.21
Shares Outstanding1,473,827,485
10 Day Avg. Volume5,337,836
30 Day Avg. Volume5,836,001
Standard Deviation0.06
R-Squared0.42
Alpha0.00460
Financial Highlights & Ratios
PEG Ratio1.56
Price to Book (P/B)6.48
Price to Sales (P/S)8.32
Price to Cash Flow (P/CF)33.00
P/FCF Ratio37.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.98
Enterprise Value/Gross Profit14.44
Enterprise Value/Ebitda38.35
Forecast
1Y Price Target
$100.65Price Target Upside10.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Boston Scientific News
PremiumCompany Announcements
Boston Scientific Launches 2025 Incentive ProgramsBulls Say, Bears Say
Bulls Say
Business GrowthA confident tone in the structural growth of BSX’s Urology business is seen as under-modelled by the street and a source of upside.
Clinical TrialsOPTION trial results suggest a significant, incremental opportunity near term, while CHAMPION should expand WATCHMAN-eligibility longer-term.
Product DevelopmentIntegration of mapping into BSX's PFA platform is seen as a significant development, with PFA penetration expected to exceed expectations.
Bears Say
Clinical Trial OutcomesThe ACURATE IDE trial did not meet its non-inferiority endpoint, with higher rates of all-cause mortality, stroke, or rehospitalization in the neo2 arm compared to the control arm.
Growth ConcernsThere is a belief that BSX's organic growth may have reached a near-term peak, and there is concern that investors may increasingly worry about BSX's growth slowing as it laps its outstanding 2024 results and new PFA competitors enter the market.
Regulatory ChallengesThe future of the neo2 valve in the United States is uncertain, and it likely requires another trial to gain market approval due to safety concerns.
---
Ownership Overview
0.17% Insiders
29.78% Mutual Funds
18.60% Other Institutional Investors
31.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $55.75 and its highest was $91.93 in the past 12 months.
What is Boston Scientific’s market cap?
Currently, no data Available
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Jan 29, 2025 which is in 34 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Oct 23, 2024. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.588 by $0.042.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is $0.66.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,473,827,500 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.63 in its last earnings report, beating expectations of $0.588. Following the earnings report the stock price went down -0.636%.
Which hedge fund is a major shareholder of Boston Scientific?
Among the largest hedge funds holding Boston Scientific’s share is PRIMECAP Management Co. It holds Boston Scientific’s shares valued at 3B.
---
Boston Scientific Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.65 (10.52% Upside)
$100.65 (10.52% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $446.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.91%
12-Months-Change
Fundamentals
Return on Equity
9.05%
Trailing 12-Months
Asset Growth
11.85%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.
---
BSX Company Deck
---
BSX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Boston Scientific reported strong revenue and EPS growth, driven by standout performances in operational regions and the electrophysiology segment. However, there were challenges in the Neuromodulation segment and a temporary pause in the AVANT GUARD trial. Despite these issues, the company's financial outlook remains positive.Read More>---
BSX Revenue Breakdown
61.93% Cardiovascular
38.08% MedSurg
---
BSX Stock 12 Month Forecast
Average Price Target
$100.65
▲(10.52% Upside)
Technical Analysis
Best Analysts Covering BSX
1 Year
1 Year Success Rate
20/20 ratings generated profit
1 Year Average Return
+31.34%
reiterated a buy rating 6 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.34% per trade.
---